Compare Adaptive Biotechnologies Corp (ADPT) vs Xcel Energy Inc (XEL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Xcel Energy Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Xcel Energy Inc trades at $79.57 (market cap $50.36B). The key difference: Xcel Energy Inc is far larger — about 15.1× Adaptive Biotechnologies Corp's market cap, and Xcel Energy Inc pays a 2.94% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | XEL | |
|---|---|---|
Market Cap | $3.33B | $50.36B |
Sector | Health | Utilities |
52-Week High | $22.37 | $83.91 |
52-Week Low | $10.24 | $67.56 |
Enterprise Value | $3.19B | $87.80B |
Dividend Yield | — | 2.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Xcel Energy (XEL) trades at $80.67, down 1.57% on the day, with a bullish technical signal and strong analyst support (17 buy ratings). The stock shows steady revenue growth, with 2025 revenue at $14.67 billion and net income of $2.02 billion, though recent quarters saw mixed earnings results. A $60 billion capital expenditure plan through 2030 aims to capitalize on rising electricity demand from data centers and electrification trends.
The outlook is positive, supported by a consensus price target of $91.50, implying 13% upside. Key risks include regulatory pushback on rate hikes and high debt levels, with debt-to-assets at 41.64% in 2025. The dividend yield of 2.87% adds income appeal, but investors should monitor execution of the expansive capex plan and regulatory approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Xcel Energy Inc
Xcel Energy manages utilities serving 3.7 million electric customers and 2.1 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan
Read more on XEL →
